Beta-Blocker Therapy with Metoprolol and Propranolol

Introduction to Beta-Blockers

The American College of Cardiology recommends metoprolol, a cardioselective beta-blocker, for patients with respiratory conditions due to its preferential blocking of beta-1 receptors at lower doses 1, 2

Metoprolol is a beta-1 selective adrenergic receptor blocker, affecting primarily cardiac tissue, while propranolol is non-selective, blocking both beta-1 and beta-2 receptors, affecting both cardiac tissue and bronchial/vascular smooth muscle 1, 2
The American Heart Association suggests that metoprolol is preferred in patients with bronchospastic airway disease requiring beta blockade due to its relative beta-1 selectivity 1, 2

The American College of Cardiology recommends metoprolol tartrate at 100-200 mg daily in 2 divided doses 1, 2
The American Heart Association suggests metoprolol succinate (extended-release) at 50-200 mg once daily 2, 3
Initial dosing for hypertension with metoprolol tartrate is 25-50 mg twice daily, and for metoprolol succinate, it is 50-100 mg once daily 3
Propranolol immediate release (IR) is recommended at 80-160 mg daily in 2 divided doses, and propranolol long-acting (LA) at 80-160 mg once daily 1, 2

The American College of Cardiology states that bisoprolol and metoprolol succinate are preferred in patients with heart failure with reduced ejection fraction (HFrEF) 2
Carvedilol is also preferred in HFrEF patients, according to the American Heart Association 2
Propranolol is not specifically indicated for heart failure management, as stated by the American College of Cardiology 1, 2
Gradual tapering of both medications is required to avoid rebound hypertension, worsening angina, or potential cardiac events, with metoprolol tapering reducing dose by 25-50% every 1-2 weeks 2, 3

Marked first-degree AV block (PR interval >0.24 seconds), second or third-degree heart block without a pacemaker, cardiogenic shock, or decompensated heart failure are contraindications for both drugs, as stated by the American Heart Association 4

Blood pressure and heart rate should be monitored regularly with both medications, according to the American College of Cardiology 3

The American College of Cardiology and American Heart Association guidelines recommend avoiding abrupt cessation of metoprolol in hypertension management, as it can lead to severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias, and all beta-blockers including metoprolol tartrate and metoprolol succinate carry this warning 5, 6

In post-MI patients, the American College of Cardiology strongly recommends beta-blockers, including metoprolol, for secondary prevention, and abrupt withdrawal can lead to clinical deterioration 7
In heart failure with reduced ejection fraction (HFrEF), the American College of Cardiology recommends metoprolol succinate as a preferred agent, and abrupt withdrawal should be avoided even if symptoms improve 7
The American College of Cardiology also warns that patients with heart failure are at high risk from abrupt discontinuation of metoprolol, as it can precipitate acute decompensation 7